Dr. Induru Discusses Other Mutations in Lung Cancer

Raghava R. Induru, MD
Published: Monday, Nov 20, 2017



Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

EGFR, ALK, and ROS1, are the most well-known molecular subtypes of lung cancer, and have been used to develop effective treatments, but there are other targets that may help guide treatment.

Of these other targets, BRAF mutations and NTRK mutations are most notable, says Induru. The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) is FDA approved for BRAF-mutated tumors, and entrectinib is showing promise in NTRK-mutated tumors.
 


Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

EGFR, ALK, and ROS1, are the most well-known molecular subtypes of lung cancer, and have been used to develop effective treatments, but there are other targets that may help guide treatment.

Of these other targets, BRAF mutations and NTRK mutations are most notable, says Induru. The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) is FDA approved for BRAF-mutated tumors, and entrectinib is showing promise in NTRK-mutated tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x